Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Breast cancer drug could halt other tumors

The drug, geldanamycin, is well known for attacking a protein associated with the spread of breast cancer. However, a laboratory-based study found it also degraded a different protein that triggers blood vessel growth.
Stopping unwanted blood vessel growth is a key challenge in the battle against cancer, according to Dr Sreenivasan Ponnambalam, reader in human disease biology in the University of Leeds' Faculty of Biological Sciences.

"This is potentially very significant because tumours secrete substances that stimulate blood vessels to develop around them, forming networks that supply nutrients and provide pathways for spread around the body," Dr Ponnambalam said. "This is one of the big problems in cancer: how can we stop the tumour growing and spreading through these blood vessel networks?"

There are already other drugs available that try to stop this growth. One type tries to attack directly the membrane protein VEGFR2, which is essential for new blood vessel growth. However, that approach carries the risk of serious side-effects because proteins in the membrane walls of blood vessels do important work such as controlling blood pressure.

Geldanamycin offers a novel and potentially safer solution because it suppresses the protein indirectly.

The new study, based on experiments with human cells and different animal models, found that geldanamycin indirectly triggered the clearance of the VEGFR2 protein by activating a cellular quality-control system that breaks down many proteins.

That quality-control system already degrades VEGFR2 relatively slowly but the drug accelerates the process, preventing activation of the protein and inappropriate new blood vessel formation.

"With conventional treatments, we have been trying to deal with the situation after the switch has been thrown. What this drug does is destroy the key part of the switch before that switch is thrown," Dr Ponnambalam said.

"Geldanamycin and chemical derivatives have been under intensive study in the laboratory and in clinical trials for the past 20 years. The cost to the NHS or patients could be relatively low compared to the expensive existing anti-cancer drugs, which are still under patent," Dr Ponnambalam added.

The two-year study involved researchers in the University of Leeds and University College London. It was funded by The Wellcome Trust. The paper is published in the journal PLOS ONE.

Notes for editors

Contact: Chris Bunting, Press Officer, University of Leeds; phone: +44 113 343 2049 or email

The full paper: A.F Bruns N. Yuldasheva, A.M. Latham, Caroline Pellet-Many, L. Bao, P. Frankel, S.L. Stephen, G.J. Howell, S.B. Wheatcroft, M.T. Kearney, I.C. Zachary, S. Ponnambalam, "A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair." PLOS ONE (2012)

Chris Bunting | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>